Claudio Gasperini

Claudio Gasperini

Auto-generated profile, based on publicly available information

Claudio Gasperini

Department of Neurosciences, S. Camillo-Forlanini Hospital, Rome, Italy

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in The Lancet Neurology
Verified
Journal Article
Open access
Massimo FilippiMassimo Filippi
Massimo Filippi
MRMaria A Rocca
Maria A Rocca
OCOlga Ciccarelli
Olga Ciccarelli
NSNicola De Stefano
Nicola De Stefano
NENikos Evangelou
Nikos Evangelou
FBFrederik Barkhof
Frederik Barkhof
In patients presenting with a clinically isolated syndrome, MRI can support and substitute clinical information in the diagnosis of multiple sclerosis by showing disease dissemination in space and time and by helping to exclude disorders that can mimic multiple sclerosis. MRI criteria were first included in the diagnostic work-up for multiple sclerosis in 2001, and since then several modifications to the criteria have been proposed in an attempt to simplify lesion-count models for showing disease dissemination in space, change the timing of MRI scanning to show dissemination in time, and increase the value of spinal cord imaging. Since the last update of these criteria, new data on the use of MRI to establish dissemination in space and time have become available, and MRI technology has improved. State-of-the-art MRI findings in these patients were discussed in a MAGNIMS workshop, the goal of which was to provide an evidence-based and expert-opinion consensus on proposed modifications to MRI criteria for the diagnosis of multiple sclerosis.

1 March 2011 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ANA. Novotna
A. Novotna
JMJ. Mares
J. Mares
SRS. Ratcliffe
S. Ratcliffe
INI. Novakova
I. Novakova
MVM. Vachova
M. Vachova
TGthe Sativex Spasticity Study Group
the Sativex Spasticity Study Group

1 March 1999 in The Lancet
Verified
Journal Article
Closed access
LKLudwig Kappos
Ludwig Kappos
DMDavid Moeri
David Moeri
ERErnst Wilhelm Radue
Ernst Wilhelm Radue
ASAndreas Schoetzau
Andreas Schoetzau
KSKati Schweikert
Kati Schweikert
Massimo FilippiMassimo Filippi
Massimo Filippi

14 September 2004 in Neurology
Verified
Journal Article
Closed access
PDF file
CSClaudio Solaro
Claudio Solaro
GBG. Brichetto
G. Brichetto
MAM. P. Amato
M. P. Amato
ECE. Cocco
E. Cocco
BCB. Colombo
B. Colombo
TGthe PaIMS Study Group
the PaIMS Study Group
In a multicenter cross-sectional study, the authors assessed pain in patients with multiple sclerosis (MS) using a symptom-oriented approach. Out of 2,077 questionnaires, we used 1,672 for data analysis. Pain and frequencies included trigeminal neuralgia 2%, Lhermitte’s sign 9%, dysesthetic pain 18.1%, back pain 16.4%, and painful tonic spasms 11%. Comparison between different groups showed significant differences for age, Expanded Disability Status Scale, disease duration, and disease course, but not for sex. This study underlines the relevance of pain in the clinical history of MS.

20 February 1997 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
EME. Millefiorini
E. Millefiorini
CGC. Gasperini
C. Gasperini
CPC. Pozzilli
C. Pozzilli
FDF. D'Andrea
F. D'Andrea
ABA. Bozzao
A. Bozzao
SMS. Morino
S. Morino

14 April 2020 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
JCJames H. Cole
James H. Cole
JRJoel Raffel
Joel Raffel
TFTim Friede
Tim Friede
AEArman Eshaghi
Arman Eshaghi
WBWallace J. Brownlee
Wallace J. Brownlee
MGMAGNIMS study group
MAGNIMS study group
Objective: During the natural course of multiple sclerosis (MS), the brain is exposed to aging as well as disease effects. Brain aging can be modeled statistically; the so‐called “brain‐age” paradigm. Here, we evaluated whether brain‐predicted age difference (brain‐PAD) was sensitive to the presence of MS, clinical progression, and future outcomes.Methods: In a longitudinal, multicenter sample of 3,565 magnetic resonance imaging (MRI) scans, in 1,204 patients with MS and clinically isolated syndrome (CIS) and 150 healthy controls (mean follow‐up time: patients 3.41 years, healthy controls 1.97 years), we measured “brain‐predicted age” using T1‐weighted MRI. We compared brain‐PAD among patients with MS and patients with CIS and healthy controls, and between disease subtypes. Relationships between brain‐PAD and Expanded Disability Status Scale (EDSS) were explored.Results: Patients with MS had markedly higher brain‐PAD than healthy controls (mean brain‐PAD +10.3 years; 95% confidence interval [CI] = 8.5–12.1] versus 4.3 years; 95% CI = 2.1 to 6.4; p < 0.001). The highest brain‐PADs were in secondary‐progressive MS (+13.3 years; 95% CI = 11.3–15.3). Brain‐PAD at study entry predicted time‐to‐disability progression (hazard ratio 1.02; 95% CI = 1.01–1.03; p < 0.001); although normalized brain volume was a stronger predictor. Greater annualized brain‐PAD increases were associated with greater annualized EDSS score (r = 0.26; p < 0.001).Interpretation: The brain‐age paradigm is sensitive to MS‐related atrophy and clinical progression. A higher brain‐PAD at baseline was associated with more rapid disability progression and the rate of change in brain‐PAD related to worsening disability. Potentially, “brain‐age” could be used as a prognostic biomarker in early‐stage MS, to track disease progression or stratify patients for clinical trial enrollment. ANN NEUROL 2020 ANN NEUROL 2020;88:93–105